These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31170171)

  • 1. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil.
    Demitto FO; Schmaltz CAS; Sant'Anna FM; Arriaga MB; Andrade BB; Rolla VC
    PLoS One; 2019; 14(6):e0217014. PubMed ID: 31170171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors impacting early mortality in tuberculosis/HIV patients: differences between subjects naïve to and previously started on HAART.
    Schmaltz CA; Santoro-Lopes G; Lourenço MC; Morgado MG; Velasque Lde S; Rolla VC
    PLoS One; 2012; 7(9):e45704. PubMed ID: 23049842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS.
    Sant'Anna FM; Velasque L; Costa MJ; Schmaltz CA; Morgado MG; Lourenço MC; Grinsztejn B; Rolla VC
    Braz J Infect Dis; 2009 Oct; 13(5):362-6. PubMed ID: 20428637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of antiretrovirals for people with HIV.
    Kredo T; Van der Walt JS; Siegfried N; Cohen K
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007268. PubMed ID: 19588422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.
    Caro-Vega Y; Schultze A; W Efsen AM; Post FA; Panteleev A; Skrahin A; Miro JM; Girardi E; Podlekareva DN; Lundgren JD; Sierra-Madero J; Toibaro J; Andrade-Villanueva J; Tetradov S; Fehr J; Caylà J; Losso MH; Miller RF; Mocroft A; Kirk O; Crabtree-Ramírez B
    BMC Infect Dis; 2018 Apr; 18(1):191. PubMed ID: 29685113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report.
    Mohzari YA; Musawa MA; Alrashed A; Zaeri B; Damfu N; Cahusac P; Alwafai S; Alamer A; Almulhim A
    J Infect Public Health; 2023 Dec; 16(12):2026-2030. PubMed ID: 37890226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients.
    da Silva TP; Giacoia-Gripp CBW; Schmaltz CA; Sant'Anna FM; Saad MH; Matos JA; de Lima E Silva JCA; Rolla VC; Morgado MG
    BMC Infect Dis; 2017 Sep; 17(1):606. PubMed ID: 28874142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy.
    Worodria W; Massinga-Loembe M; Mazakpwe D; Luzinda K; Menten J; Van Leth F; Mayanja-Kizza H; Kestens L; Mugerwa RD; Reiss P; Colebunders R;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):32-7. PubMed ID: 21654499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
    BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality and survival of tuberculosis coinfected patients living with AIDS in São Paulo, Brazil: a 12-year cohort study.
    Tancredi MV; Sakabe S; Waldman EA
    BMC Infect Dis; 2022 Mar; 22(1):223. PubMed ID: 35246066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.
    Nagu TJ; Aboud S; Mwiru R; Matee MI; Rao M; Fawzi WW; Zumla A; Maeurer MJ; Mugusi F
    Int J Infect Dis; 2017 Mar; 56():39-44. PubMed ID: 28161460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful integration of tuberculosis and HIV treatment in rural South Africa: the Sizonq'oba study.
    Gandhi NR; Moll AP; Lalloo U; Pawinski R; Zeller K; Moodley P; Meyer E; Friedland G;
    J Acquir Immune Defic Syndr; 2009 Jan; 50(1):37-43. PubMed ID: 19295333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.
    OʼDonnell MR; Wolf A; Werner L; Horsburgh CR; Padayatchi N
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):22-9. PubMed ID: 24872138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.
    Amani-Bosse C; Dahourou DL; Malateste K; Amorissani-Folquet M; Coulibaly M; Dattez S; Emieme A; Barry M; Rouzioux C; N'gbeche S; Yonaba C; Timité-Konan M; Mea V; Ouédraogo S; Blanche S; Meda N; Seguin-Devaux C; Leroy V
    J Int AIDS Soc; 2017 Apr; 20(1):21362. PubMed ID: 28453240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
    Schmaltz CAS; Demitto FO; Sant'Anna FM; Rolla VC
    Mem Inst Oswaldo Cruz; 2019 Feb; 114():e180420. PubMed ID: 30758392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
    Wake RM; Poulikakos P; Groth J; Harrison TS; Macallan DC
    Int J STD AIDS; 2013 Apr; 24(4):263-8. PubMed ID: 23635810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.